Five-year survival for all pediatric cancers increased from 63 percent in mid-1970s to 87 percent in 2015 to 2021.

When cancer subtypes were examined, the analysis revealed that phototherapy was linked to a 40% increased odds of blood cancers. More modest associations were observed for solid organ cancers and ...

In order to understand how patients are affected by receiving notification of their breast density, Australian researchers conducted a randomized, multi-arm trial of 2401 women with dense breasts.

FZOCUS-1 assessed the safety and efficacy of fuzuloparib alone and in combination with apatinib for patients with newly diagnosed or advanced ovarian cancer.

Researchers conducted a retrospective analysis of patients treated with ICI therapy who had undergone esophagogastroduodenoscopy after starting treatment to assess for immunotherapy-related gastritis ...

Median progression-free survival was 22 months, overall survival was 152 months among patients with newly diagnosed MM.

Researchers reported on patient acceptance of an e-consent tool for asynchronous delivery of study information and for receiving consent from patients.

Researchers investigated non-melanoma skin cancer prevalence among sexual orientation identities by race/ethnicity and gender.

Among a heavily pretreated, older adult population of patients with relapsed/refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML), revumenib was associated with a clinically ...

PRRT retreatment may be well tolerated and confer a survival benefit in patients with well-differentiated, metastatic neuroendocrine tumors, a study suggests.

Cardiac testing identified asymptomatic, clinically significant arrhythmias in 19% of patients on ibrutinib.

Thrombotic risk with PICCs matched that of totally implantable venous access devices, showing comparable long-term safety.